Triveni Bio secured $65 million in a Series C round to advance TRIV-573, its bispecific therapy for atopic dermatitis. The financing is earmarked for clinical development, signaling continued investment in new modality pipelines aimed at inflammatory skin disease. For investors and partners, the raise highlights market appetite for next-generation bispecifics that target multiple immune pathways with the goal of improving response depth and durability for chronic, relapsing conditions like eczema. The company did not describe additional clinical milestones in the provided coverage, but the use-of-proceeds framing keeps near-term execution tied to continued clinical progress for TRIV-573.